South Korean company nabs plant that makes generic Botox

Pharma Research Products has obtained control of this BioCND plant in South Korean that manufacturers generic injectable botulinum toxin. (PRP)

PharmaResearch Products, a South Korean company focused on “regenerative” and cosmetic medicines has picked up a plant that manufactures generic injectable botulinum toxin, the same ingredient used in the popular wrinkle remover Botox.

Seongnam-si, Gyeonggi-do- based PRP said in a press release, that it had invested about $35 million to “secure" majority ownership of the botulinum toxin type A injection (ReNtox) production facility of BioCND, a South Korean Biotech that is developing biosimilars. 

The newly built, 6,000-square-meter plant, is in Gangneung-si on the East Coast of South Korea. PRP says it has an initial capacity of 2 million vials of the ReNtox per year. The BioCND plant was completed last summer, The South Korea Herald reported, and the biotech had obtained more than $870,000 in private investments to operate it. No reason was given by BioCND, which is working on several other biosimilar products, for selling control of the facility.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The plant, which has 50 employees, is not currently producing on a commercial scale, PRP said but an application for a botulinum injection biosimilar is under evaluation by South Korea's Ministry of Food and Drug Safety (MFDS), the company said in an email. A GMP inspection of the plant is expected in the second half of this year.

PRP said the acquisition of the plant completes its “proprietary line of facial esthetic products.” It already has a line of hyaluronic acid fillers and Rejuran, a micro injection filler.

RELATED: Look out, Allergan: Doctor surveys show the 'Botox competitive threat is real'

While the facility was built to meet MFDS GMP requirements, PRP said it has designs on the “worldwide facial esthetic market.” But in wider market, PRP will face competition. There are other companies currently working on biosimilars of Allergan’s big-selling Botox for the U.S. market.

PRP also has a plant under construction, slated to be complete this year, for production of some of its other products. 

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.